Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study

Table 1

Different combinations of insulin glargine and other hypoglycemic therapies evaluated 6 months after the index date (first prescription of insulin glargine).

Cohort of study	Total		Insulin-naïve		Insulin-established		value
		%		%		%
Insulin glargine only	466	6.3	293	9.9	173	3.9	<0.001
Insulin glargine+other oral glucose-lowering drugs	1,590	21.4	680	22.9	910	20.4	0.002
Insulin glargine+rapid-acting insulin	4,475	60.3	1,576	53.2	2,899	65.0	<0.001
Insulin glargine+DPP-4 inhibitors	357	4.8	167	5.6	190	4.3	0.004
Insulin glargine+other combinations	534	7.2	247	8.3	287	6.4	0.002
Total	7,422	100.0	2,963	100.0	4,459	100.0

Insulin-naïve vs. insulin-established.